Bollard Group’s Emergent Biosolutions EBS Stock Holding History

Bollard Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-127	Closed	-$1K	–	466
2023 Q2	$1K	Buy	+127	New	+$1.18K	﹤0.01%	588

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bollard Group's EBS Position: Q3 2023 in Review

Bollard Group sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 127 shares — an estimated $1K sold.

Bollard Group first reported a position in EBS in Q2 2023 and held it in 1 quarter. The position peaked at $1K in Q2 2023. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

Bollard Group reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 127 Emergent Biosolutions shares in Q3 2023, an estimated $1K.
Bollard Group first reported a position in Emergent Biosolutions in Q2 2023 and held it in 1 quarter.
Bollard Group's Emergent Biosolutions position peaked at $1K in Q2 2023.
162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.